The Efficacy of Chemotherapy against Metastatic Malignant Phyllodes Tumors of the Breast

Bourhafour, Mouna; Rhizlane, Belbaraka

doi:10.4172/2165-7920.1000122

Cited by 2 publications

(3 citation statements)

References 11 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Whereas both the stromal and epithelial cells were present in the breast tumor, only the stromal component was seen in the metastatic lesion. 10 Histopathology of the original breast tumor revealed many areas of stromal overgrowth, a feature which is strongly correlated with subsequent metastatic activity. 11 Moreover, those patients with malignant phyllodes tumors have a 20-25% incidence of distant metastasis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bone metastasis from malignant phyllodes of the breast

Dau

Sudarsa

2019

Int J Res Med Sci

View full text Add to dashboard Cite

Cystosarcoma phyllodes was described first in 1838 and originally was considered to be a benign tumor. It was not until 1931 that metastasis from a cystosarcoma phyllodes was reported. The incidence of cystosarcoma phyllodes is estimated to be 0.3% to 0.9% of all breast tumors. Sites most commonly affected by metastases are the lungs and bones. We present a case report 29-year old female patient presented with a voluminous breast mass at both of them which was completely resected. The right side presented of malignant phyllodes and the left side is borderline phyllodes. Six months later, both of her legs became paralyzed and accompanied by swelling over her right upper arm. Biopsy was performed, and the diagnosis was metastatic malignant phyllodes tumor. Histologic review of the breast tumor revealed stromal overgrowth.

show abstract

Section: Discussionmentioning

confidence: 99%

“…13 The rarity of metastatic cystosarcoma phyllodes makes it difficult to do systematic trials. 10 The efficacy of systemic chemotherapy against metastatic MPT remains unknown. It is based on the principles of sarcoma rather than carcinoma treatment.…”

Section: Discussionmentioning

confidence: 99%

Bone metastasis from malignant phyllodes of the breast

Dau

Sudarsa

2019

Int J Res Med Sci

View full text Add to dashboard Cite

show abstract

“…Interestingly, chemotherapy promotes benefit in palliative setting such as MAID (Doxorubicin, Dacarbazine, Ifosfamide, and Mesna). In retrospective analysis from breast sarcomas treated with MAID regimen, partial response was 50% with respectively DFS and OS medians of 2.5 and 5 months [4].…”

Section: Introductionmentioning

confidence: 99%

Adjuvant chemotherapy for malignant phyllodes tumor of the breast

Paula¹,

Guerra²,

Sousa³

et al. 2020

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Malignant phyllodes tumor of the breast (MPTB) is rare and usually presents as a large rapidly progressive mass which might metastasize distantly. The survival benefit of breast surgery is unquestionable; on the other hand, adjuvant radiotherapy and chemotherapy are controversial. In this study, chemotherapy endpoints are reviewed and underlying factors related to the outcomes are discussed. We performed a systematic review based on studies reporting diseasefree survival (DFS) and/or overall survival (OS) rates with chemotherapy as variable in MPTB patients. The search generated 246 studies and 3 were included. They present together 199 patients, 77 (39%) with aggressive histology and 29 (15%) received chemotherapy. One study reported better DFS and OS outcomes in treatment group whilst two reported the opposite, but neither results were statistically significant. Unbalanced arms, small sample size, absence of prognostic factors stratification and inclusion of indolent subtypes are factors that might have contributed to these results. Therefore, the negative benefit of adjuvant chemotherapy in survival of MPTB is based on few studies with considerable limitations. High risk MPTB should be properly studied in randomized prospective trials, specially taking into account prognostic and predictive molecular markers of response.

show abstract

The Efficacy of Chemotherapy against Metastatic Malignant Phyllodes Tumors of the Breast

Cited by 2 publications

References 11 publications

Bone metastasis from malignant phyllodes of the breast

Bone metastasis from malignant phyllodes of the breast

Adjuvant chemotherapy for malignant phyllodes tumor of the breast

Contact Info

Product

Resources

About